Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment.
Saved in:
| Title: | Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. |
|---|---|
| Authors: | Ferrari S; Geneva University Hospital, Geneva, Switzerland., Butler PW; Amgen Inc., Thousand Oaks, California., Kendler DL; University of British Columbia, Vancouver, British Columbia, Canada., Miller PD; Colorado Center for Bone Research, Lakewood, Colorado., Roux C; Paris Descartes University, Paris, France., Wang AT; Amgen Inc., Thousand Oaks, California., Huang S; Amgen Inc., Thousand Oaks, California., Wagman RB; Amgen Inc., Thousand Oaks, California., Lewiecki EM; New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico. |
| Source: | The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2019 Aug 01; Vol. 104 (8), pp. 3450-3461. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1945-7197 |
|---|---|
| DOI: | 10.1210/jc.2019-00271 |
